Interrelationship of Chlorophenoxyisobutyrate, Ubiquinone, and Cholesterol
Administration of α-p-chlorophenoxyisobutyrate (CPIB), the serum-cholesterol depressing drug (1), is known to act at a site before mevalonate in the hepatic synthesis of cholesterol (2) but indirectly by some metabolic alteration. That this may be ubiquinone metabolism was indicated by our discovery that ubiquinone accumulated in the livers of rats fed CPIB (3). Similar accumulation was obtained with dietary ubiquinone (4) which also produced the twin effects of inhibition of hepatic cholesterol synthesis prior to mevalonate (4,5) and decrease in serum-cholesterol concentration (3). It will be shown here that parallel effects are obtained by feeding either ubiquinone or CPIB supporting the hypothesis that ubiquinone is the natural regulatory molecule in the biogenesis of hepatic cholesterol.
KeywordsKetone Body Domestic Sewage Hepatic Cholesterol Feeding Regimen Hepatic Synthesis
Unable to display preview. Download preview PDF.
- 5.Ramasarma, T., Joshi, V.C., Inamdar, A.R., Aithal, H.N. & Krishnaiah, K.V. Progress Biochem. Pharmacol. 2: 56 (1967).Google Scholar
- 9.Inamdar, A.R. & Ramasarma, T. Biochem. J. in press.Google Scholar
- 12.Aiyar, A.S. & Sreenivasan, A. J. Sci. industr. Res. (India) 21A: 559 (1962).Google Scholar
- 13.Hegsted, D.M., Gotsis, A. & Stare, F.J. J. Nutr. 63: 277 (1957).Google Scholar
- 17.Krishna Murthi, C.R. & Varma, V. J. Sci. industr. Res. (India) 19C: 180 (1960).Google Scholar